Conditions: Diabetes Mellitus, Type 2
Keywords: T2DM PF-04937319 Phase 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 304
Healthy volunteers: no

Brief summary:
This is a study to understand efficacy and safety of investigational agent (PF-04937319) compared to approved agent (glimepiride) in patients with diabetes on metformin

Detailed description:

Arms:
arm 1: Placebo to match PF-04937319 and glimepiride arm 2: None arm 3: None arm 4: None arm 5: None

Interventions: intervention 1: Placebo intervention 2: PF-04937319 10 mg intervention 3: PF-04937319 50 mg intervention 4: PF-04937319 100 mg intervention 5: Glimepiride
Intervention descriptions: intervention 1: Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days intervention 2: Combination of tablets and capsules, dose of 10 mg, a total of 3 pills/dose, administered once daily for 84-days intervention 3: Combination of tablets and capsules, dose of 50 mg, a total of 3 pills/dose, administered once daily for 84-days intervention 4: Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days intervention 5: Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days

Protocol document: